NCCN Pharmacy Updates: Webinar Series
The availability of new therapeutic options and emergence of novel therapieaches continues to dramatically impact the oncology landscape. The rapid integration of these agents into treatment for various tumor types can be challenging for clinicians. Pharmacists are critical to educating the interprofessional oncology care team about the actions and potential adverse events associated with new and existing therapeutic options. Pharmacists also have an important role in patient education as well as subsequent monitoring and management of treatment-related toxicities.
NCCN Pharmacy Updates: A Webinar Series is designed for pharmacists and the oncology care team to review the clinical and patient considerations that influence how to effectively optimize management of patients with various cancer types. Webinars will cover the following topics: pediatric acute lymphoblastic leukemia, kidney cancer, pediatric B-cell non-Hodgkin’s lymphomas, neuroendocrine tumors, breast cancer, lung cancer, acute myeloid leukemia, immunotherapy-related toxicities, smoking cessation, venous thromboembolism, transplant, and biosimilars. Webinars will be case-based and designed to provide an overview of a specific disease state and will include content on new and emerging therapies, dosing, efficacy, toxicity management and adverse events.
This educational program is designed to meet the educational needs of pharmacists, physicians, nurses, nurse practitioners, physician assistants and other health care professionals who manage patients with cancer.
The goal of this project is to ensure that pharmacists, physicians, nurses, nurse practitioners, physician assistants, and other members of the interprofessional oncology care team who manage patients with cancer have the knowledge and skills necessary to:
- Apply the current standards of oncology care and NCCN Clinical Practice Guidelines in Oncology to optimize the management of patients with various cancer types.
- Review new, emerging, and novel therapeutic agents and treatment strategies and incorporate these into the management of patients with cancer.
- Communicate the importance of a multidisciplinary approach and improve the collaborative performance of the interprofessional oncology care team in the management of patients with cancer.
Novel Treatments for Neuroendocrine Tumors
Monday, September 28, 2020 • 3:00 – 4:00 PM EDT
Salvatore Bottiglieri, PharmD, BCOP, Moffitt Cancer Center
Establishing a Place in Therapy for Biosimilars in Oncology
Wednesday, October 28, 2020 • 12:30 – 1:30 PM EDT
Rebecca J. Nelson, PharmD, BCOP, Moffitt Cancer Center
Treatment Advances for Pediatric B-Cell Non-Hodgkin's Lymphomas
Tuesday, November 17, 2020 • 4:00 – 5:00 PM EST
Diana Wu, PharmD, BCPS, BCOP, St. Jude Children’s Research Hospital
Emerging Strategies in the Treatment of Venous Thromboembolism
Tuesday, December 8, 2020 • 2:00 – 3:00 PM EST
ALL WEBINAR TIMES ARE POSTED AS EASTERN DAYLIGHT TIME (EDT) (UTC/GMT -4:00) OR EASTERN STANDARD TIME (EST) (UTC/GMT -5:00).
Access to participate in selected sessions is through the NCCN WebEx Site on the day of each scheduled program.
The most recent recorded webcasts from this series are listed below.
- Emerging Strategies for Pediatric Acute Lymphoblastic Leukemia Management (held on January 29, 2020, and presented by Michael Stanton, PharmD, BCOP, Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute)
- Advances in Targeted Therapy and Immunotherapy for the Treatment of Kidney Cancer (held on February 12, 2020, and presented by Kirollos S. Hanna, PharmD, BCPS, BCOP, Mayo Clinic College of Medicine and University of Minnesota Medical Center)
- Current Therapy Options for Graft-Versus-Host Disease (held on April 1, 2020, and presented by Cynthia Herrera, PharmD, BCPS, BCOP, Robert H. Lurie Comprehensive Cancer Center of Northwestern University)
- New Targets and Treatment Options for Acute Myeloid Leukemia (held on April 28, 2020, and presented by Daniel Wojenski, PharmD, BCPS, BCOP, Robert H. Lurie Comprehensive Cancer Center of Northwestern University)
- Updates on the Use of Immunotherapy and Targeted Therapy in Non-Small Cell Lung Cancer (held on May 21, 2020, and presented by Jennifer Piccolo, PharmD, BCOP, William S. Middleton Memorial Veterans Hospital)
- The Role of the Pharmacist in Smoking Cessation and Education of Patients with Cancer (held on June 8, 2020, and presented by Kelly Gaffney, PharmD, BCOP, Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute)
- New Targets in Breast Cancer Therapy (held on July 28, 2020, and presented by Craig Vargo, PharmD, BCOP, The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute)
- Assessment and Management of CAR T-Cell Related Toxicities (held on August 25, 2020, and presented by Helen Marshall, PharmD, BCPS, BCOP, Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance)
NCCN Medical Education Disclosure Policy
It is the policy of NCCN that every 12 months, all faculty, moderators, activity planners and all internal planning staff participating in NCCN continuing education activities are expected to disclose any financial relationships with a commercial interest as defined by the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support. In addition, all faculty presentations have been reviewed for adherence to the ACCME’s Standards for Commercial Support (the provider develops activities/educational interventions independent of commercial interests [SCS 1, 2 and 6] by experts on the topics).
Per the ACCME Standards for Commercial Support, individuals who do not disclose relevant financial relationships will be disqualified from involvement in the CE activity as a content developer, planner, or presenter. A complete list of individuals’ relationships with external entities is available upon request.
NCCN continuing education considers financial relationships to create a “conflict of interest” when an individual has both a financial relationship with a commercial interest and the opportunity to affect CE content about the products or services of a commercial interest with which he/she and/or a spouse or partner has a financial relationship.
NCCN continuing education considers “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that create a conflict of interest. NCCN does not set a minimal dollar amount for relationships to be significant. Inherent in any amount is the incentive to maintain or increase the value of the relationship.
All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.
Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling.
Full disclosure of faculty relationships will be made prior to the activity.
In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
NCCN designates each live activity in this series for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
NCCN designates each educational activity in this series for a maximum of 1.0 contact hour.
NCCN designates each application-based continuing education activity in this series for 1.0 contact hour (0.10 CEUs) of continuing education credit.
NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. Each activity in this series is designated for 1.0 AAPA Category 1 CME credit. PAs should only claim credit commensurate with the extent of their participation.
Available for an additional fee ($49 per activity): each activity is worth 1 hour of BCOP credit
The Hematology/Oncology Pharmacy Association (HOPA) is accredited by the Board of Pharmacy Specialties (BPS) as a provider of board certification oncology credit (BCOP). A BCOP statement of credit will be issued only upon completion of a post-activity evaluation form and post-test, with a passing grade of 75% achieved.
Disclosure of Conflicts of Interest: The Hematology/Oncology Pharmacy Association (HOPA) assesses conflict of interest with its instructors, planners, managers, and other individuals who are in a position to control the content of CE activities. All relevant conflicts of interest that are identified are thoroughly vetted by HOPA for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. HOPA is committed to providing its learners with high-quality CE activities and related materials that promote improvements of quality in healthcare and not a specific proprietary business interest of a commercial interest.
Reported Areas of Conflict: Hematology/Oncology Pharmacy Association does not view the existence of relationships as an implication of bias or that the value of the material is decreased. The content of the activity was planned to be balanced, objective, and scientifically rigorous. Occasionally, authors may express opinions that represent their own viewpoint. Conclusions drawn by participants should be derived from objective analysis of scientific data. Unlabeled/unapproved uses of drugs. All faculty have indicated that they have not referenced unlabeled/unapproved uses of drugs and devices.
Please refer to the Schedule tab for dates and times. Check the webinars you would like to attend and click Enroll.
To complete this activity, users will need:
- A device with an Internet connection and sound playback capability
- One of the two latest versions of Google Chrome, Mozilla Firefox, or Safari
- Internet Explorer is no longer supported
- Adobe Reader or other PDF reader software for certificate viewing/printing